{"id":50943,"date":"2022-11-16T14:00:25","date_gmt":"2022-11-16T13:00:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/short-bowel-syndrome-drug-pipeline-research-report-2022-comprehensive-insights-about-18-companies-and-20-pipeline-drugs-researchandmarkets-com\/"},"modified":"2022-11-16T14:00:25","modified_gmt":"2022-11-16T13:00:25","slug":"short-bowel-syndrome-drug-pipeline-research-report-2022-comprehensive-insights-about-18-companies-and-20-pipeline-drugs-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/short-bowel-syndrome-drug-pipeline-research-report-2022-comprehensive-insights-about-18-companies-and-20-pipeline-drugs-researchandmarkets-com\/","title":{"rendered":"Short Bowel Syndrome Drug Pipeline Research Report 2022 – Comprehensive Insights About 18+ Companies and 20+ Pipeline Drugs – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Short Bowel Syndrome – Pipeline Insight, 2022”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThis “Short Bowel Syndrome – Pipeline Insight, 2022” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Short Bowel Syndrome pipeline landscape.\n<\/p>\n

\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.\n<\/p>\n

\nReport Highlights<\/strong>\n<\/p>\n

\nThe companies and academics are working to assess challenges and seek opportunities that could influence in Short Bowel Syndrome R&D. The therapies under development are focused on novel approaches to treat\/improve in Short Bowel Syndrome.\n<\/p>\n

\nIn April 2021, 9 Meters Biopharma entered into a collaboration with the Duke Clinical Research Institute (DCRI) to support the clinical development of 9 Meters’ candidate NM-002, a proprietary long-acting GLP-1 agonist, currently in Phase 2 development for short bowel syndrome (SBS).\n<\/p>\n

\nThis segment of the Short Bowel Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.\n<\/p>\n

\nShort Bowel Syndrome Emerging Drugs<\/strong>\n<\/p>\n

\nGlepaglutide: Zealand Pharma<\/strong>\n<\/p>\n

\nGlepaglutide is a long-acting GLP-2 analog in development as a potential treatment option for short bowel syndrome (SBS). Glepaglutide is being developed as a liquid product in an autoinjector designed for subcutaneous administration, aimed to reduce, or eliminate, the need for parenteral support in people living with SBS. Currently the product is in Phase III stage of development for the treatment of Short Bowel Syndrome\n<\/p>\n

\nShort Bowel Syndrome: Therapeutic Assessment<\/strong>\n<\/p>\n

\nThis segment of the report provides insights about the different Short Bowel Syndrome drugs segregated based on following parameters that define the scope of the report, such as:\n<\/p>\n

\nMajor Players in Short Bowel Syndrome<\/strong>\n<\/p>\n

\nThere are approx. 18+ key companies which are developing the therapies for Short Bowel Syndrome. The companies which have their Short Bowel Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Zealand Pharma\n<\/p>\n

\nPhases<\/strong>\n<\/p>\n

\nThis report covers around 20+ products under different phases of clinical development like<\/strong>\n<\/p>\n